Celltrion's SteQeyma gets EC approval for inflammatory diseases
The European Commission approved Celltrion's SteQeyma, a biosimilar to Stelara, for chronic inflammatory conditions. SteQeyma, effective against IL-12 and IL-23, offers subcutaneous and intravenous formulations. It matches Stelara in efficacy and safety, marking Celltrion's seventh EU-approved biosimilar, enhancing access to affordable biologics.
Reference News
The European Commission approved Celltrion's SteQeyma, a biosimilar to Stelara, for chronic inflammatory conditions. SteQeyma, effective against IL-12 and IL-23, offers subcutaneous and intravenous formulations. It matches Stelara in efficacy and safety, marking Celltrion's seventh EU-approved biosimilar, enhancing access to affordable biologics.
The European Commission approved SteQeyma®, an ustekinumab biosimilar, for treating chronic inflammatory diseases, based on Phase III study results showing its similarity to Stelara® in efficacy and safety for moderate to severe plaque psoriasis. This approval enhances Celltrion's immunology portfolio, offering patients affordable, high-quality biologic therapies.